Tatva Chintan Pharma Chem Limited (NSE:TATVA)

India · Delayed Price · Currency is INR

1,750.00

-34.20 (-1.92%)

Oct 1, 2026, 3:29 PM IST

Market Cap	40.78B +72.3%
Revenue (ttm)	5.56B +41.1%
Net Income	513.84M +618.2%
EPS	21.97 +619.5%
Shares Out	23.39M
PE Ratio	79.33
Forward PE	53.04
Dividend	2.00 (0.11%)
Ex-Dividend Date	Sep 11, 2026

Volume	64,285
Open	1,790.00
Previous Close	1,784.20
Day's Range	1,682.90 - 1,795.00
52-Week Range	1,003.00 - 1,880.00
Beta	0.29
Analysts	Hold
Price Target	1,442.50 (-17.57%)
Est. Earnings	Oct 30, 2026

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, consumer electronics, pharmaceutical, agrochemicals, paints and coatings, dyes, and personal ... [Read more]

Industry Specialty Chemicals

Sector Materials

Founded 1996

Employees 793

Stock Exchange National Stock Exchange of India

Ticker Symbol TATVA

Full Company Profile

Financial Performance

In fiscal year 2026, Tatva Chintan Pharma Chem's revenue was 5.06 billion, an increase of 32.18% compared to the previous year's 3.83 billion. Earnings were 420.54 million, an increase of 636.11%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for TATVA stock is "Hold." The 12-month stock price target is ₹1,443, which is a decrease of -17.57% from the latest price.

Price Target

₹1,443

(-17.57% downside)

Analyst Consensus: Hold

Stock Forecasts